The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
A randomized phase 2b trial of baricitinib, an oral Janus kinase (JAK) 1/JAK2 inhibitor, in patients with moderate‐to‐severe psoriasis
Open accessAbstract
BACKGROUND: Plaque psoriasis is a chronic and often debilitating skin disorder and proinflammatory cytokines are known to play a key role in the disease process. OBJECTIVES: To evaluate the safety and efficacy of baricitinib, an oral Janus kinase (JAK) 1/JAK2 inhibitor, in patients with moderate-to-severe psoriasis in a randomized, double-blind, placebo-controlled, dose-ranging phase 2b study. METHODS: Patients were randomized (n = 271) to receive placebo or oral baricitinib at 2, 4, 8 or 10 mg once daily for 12 weeks (Part A). Dose adjustment for 12 additional weeks was based on percentage improvement in the Psoriasis Area and Severity Index (PASI) score. The primary end point was Psoriasis Area and Severity Index (PASI) 75% (PASI-75) at 12 weeks for North American patients (n = 238); secondary end points were safety and efficacy measures in the entire population. RESULTS: At week 12, more North American patients in the 8-mg (43%) and 10-mg (54%) baricitinib groups than in placebo group (17%; P < 0·05) achieved PASI-75. All baricitinib-treated groups had greater mean changes from baseline in their PASI scores (P < 0·05) at 12 weeks and (except 2 mg) had higher rates of PASI-50 than the placebo group; statistically significant PASI-90 responses were achieved in the 8-mg and 10-mg groups at 8 and 12 weeks. More than 81% of PASI-75 responders maintained their scores through 24 weeks. During Part A, study discontinuations due to adverse events (AEs) were 0%, 0%, 2·8%, 6·3% and 5·8% and treatment-emergent AE rates were 44%, 50%, 47%, 58% and 64% for placebo and 2-, 4-, 8- and 10-mg baricitinib groups, respectively. No opportunistic infections were observed in any treatment group. Dose-dependent changes in laboratory values were observed. CONCLUSIONS: Patients with moderate-to-severe psoriasis treated with baricitinib for 12 weeks achieved significant improvements in PASI-75.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nestle, F. O., Kaplan, D. H., & Barker, J. (2009) · New England Journal of Medicine · doi:10.1056/nejmra0804595 · Cited by 2,786
Global Epidemiology of Psoriasis: A Systematic Review of Incidence and Prevalence
Parisi, R., Symmons, D. P. M., Griffiths, C. E. M., & Ashcroft, D. M. (2013) · Journal of Investigative Dermatology · doi:10.1038/jid.2012.339 · Cited by 2,592
Leonardi, C. L., Kimball, A. B., Papp, K. A., Yeilding, N., Guzzo, C., Wang, Y., Li, S., Dooley, L. T., & Gordon, K. B. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60725-4 · Cited by 1,874
Self-citationLowes, M. A., Suárez-Fariñas, M., & Krueger, J. G. (2014) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032713-120225 · Cited by 1,650
Regulation of JAK–STAT signalling in the immune system
Shuai, K., & Liu, B. (2003) · Nature Reviews Immunology · doi:10.1038/nri1226 · Cited by 1,372
Papp, K. A., Langley, R. G., Lebwohl, M., Krueger, G. G., Szapary, P., Yeilding, N., Guzzo, C., Hsu, M.-C., Wang, Y., Li, S., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60726-6 · Cited by 1,361
Self-citationThe JAK-STAT Signaling Pathway: Input and Output Integration
Murray, P. J. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.5.2623 · Cited by 1,179
Etanercept as Monotherapy in Patients with Psoriasis
Leonardi, C. L., Powers, J. L., Matheson, R. T., Goffe, B. S., Zitnik, R., Wang, A., & Gottlieb, A. B. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030409 · Cited by 1,175
Reich, K., Nestle, F. O., Papp, K., Ortonne, J.-P., Evans, R., Guzzo, C., Li, S., Dooley, L. T., & Griffiths, C. E. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67566-6 · Cited by 1,045
Self-citationAdalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial
Menter, A., Tyring, S. K., Gordon, K., Kimball, A. B., Leonardi, C. L., Langley, R. G., Strober, B. E., Kaul, M., Gu, Y., Okun, M., et al. (2008) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2007.09.010 · Cited by 889
Self-citationPapp, K. A., Tyring, S., Lahfa, M., Prinz, J., Griffiths, C. E. M., Nakanishi, A. M., Zitnik, R., van de Kerkhof, P. C. M., & the Etanercept Psoriasis Study Group (2005) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2005.06688.x · Cited by 693
Self-citationPrevalence and Treatment of Psoriasis in the United Kingdom: A Population-Based Study
Gelfand, J. M., Weinstein, R., Porter, S. B., Neimann, A. L., Berlin, J. A., & Margolis, D. J. (2005) · Archives of Dermatology · doi:10.1001/archderm.141.12.1537 · Cited by 600
Convulsions with an Occult Neural-Crest Tumor
(1979) · New England Journal of Medicine · doi:10.1056/nejm197909063011016 · Cited by 404
Physiologic indirect response models characterize diverse types of pharmacodynamic effects
Jusko, W. J., & Ko, H. C. (1994) · Clinical Pharmacology and Therapeutics · doi:10.1038/clpt.1994.155 · Cited by 360
Characterization of factor XIIIa positive dermal dendritic cells in normal and inflamed skin
CERIO, R., GRIFFITHS, C. E. M., COOPER, K. D., NICKOLOFF, B. J., & HEADINGTON, J. T. (1989) · British Journal of Dermatology · doi:10.1111/j.1365-2133.1989.tb15509.x · Cited by 346
The Cytokine Network in Psoriasis
Nickoloff, B. J. (1991) · Archives of Dermatology · doi:10.1001/archderm.127.6.871 · Cited by 344
Papp, K. A., Menter, A., Strober, B., Langley, R. G., Buonanno, M., Wolk, R., Gupta, P., Krishnaswami, S., Tan, H., & Harness, J. A. (2012) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2012.11168.x · Cited by 338
Self-citation(1979) · New England Journal of Medicine · doi:10.1056/nejm197909063011015 · Cited by 291
Keystone, E. C., Taylor, P. C., Drescher, E., Schlichting, D. E., Beattie, S. D., Berclaz, P.-Y., Lee, C. H., Fidelus-Gort, R. K., Luchi, M. E., Rooney, T. P., et al. (2015) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2014-206478 · Cited by 281
Self-citationImmunocompetent cells in psoriasis: In situ immunophenotyping by monoclonal antibodies
Bos, J. D., Hulsebosch, H. J., Krieg, S. R., Bakker, P. M., & Cormane, R. H. (1983) · Archives of Dermatological Research · doi:10.1007/bf00510050 · Cited by 236
Therapeutic targeting of Janus kinases
Pesu, M., Laurence, A., Kishore, N., Zwillich, S. H., Chan, G., & O'Shea, J. J. (2008) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00644.x · Cited by 231
Shi, J. G., Chen, X., Lee, F., Emm, T., Scherle, P. A., Lo, Y., Punwani, N., Williams, W. V., & Yeleswaram, S. (2014) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.354 · Cited by 222
Boy, M. G., Wang, C., Wilkinson, B. E., Chow, V. F.-S., Clucas, A., Krueger, J. G., Gaweco, A. S., Zwillich, S. H., Changelian, P. S., & Chan, G. L. (2009) · Journal of Investigative Dermatology · doi:10.1038/jid.2009.25 · Cited by 142
Strober, B. E., Buonanno, M., Clark, J. D., Kawabata, T. T., Tan, H., Wolk, R. A., Valdez, H., Langley, R. G. B., Harness, J. A., Menter, A., et al. (2013) · British Journal of Dermatology · doi:10.1111/bjd.12517 · Cited by 99
Self-citationKeystone, E. C., Genovese, M. C., Schlichting, D. E., de la Torre, I., Beattie, S. D., Rooney, T. P., & Taylor, P. C. (2017) · The Journal of Rheumatology · doi:10.3899/jrheum.161161 · Cited by 69
Self-citationLamel, S. A., Myer, K. A., Younes, N., Zhou, J. A., Maibach, H., & Maibach, H. I. (2012) · Archives of Dermatological Research · doi:10.1007/s00403-012-1266-9 · Cited by 27
Cited by
JAK inhibition as a therapeutic strategy for immune and inflammatory diseases
Schwartz, D. M., Kanno, Y., Villarino, A., Ward, M., Gadina, M., & O'Shea, J. J. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.201 · Cited by 1,266
Banerjee, S., Biehl, A., Gadina, M., Hasni, S., & Schwartz, D. M. (2017) · Drugs · doi:10.1007/s40265-017-0701-9 · Cited by 1,206
Therapeutics targeting the IL-23 and IL-17 pathway in psoriasis
Ghoreschi, K., Balato, A., Enerbäck, C., & Sabat, R. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00184-7 · Cited by 668
Banerjee, S., Biehl, A., Gadina, M., Hasni, S., & Schwartz, D. M. (2017) · Drugs · doi:10.1007/s40265-017-0736-y · Cited by 590
JAK inhibitors in dermatology: The promise of a new drug class
Damsky, W., & King, B. A. (2017) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2016.12.005 · Cited by 530
Metadata
- Authors
- Papp, K. A., Menter, M. A., Raman, M., Disch, D., Schlichting, D. E., Gaich, C., Macias, W., Zhang, X., & Janes, J. M.
- Venue
- British Journal of Dermatology
- Publisher
- Oxford University Press (OUP)
- Published
- 2016-04-05
- Volume
- 174
- Issue
- 6
- Pages
- 1266-1276
- ISSN
- 0007-0963 (ISSN-L)
- 1365-2133
- OpenAlex
- W2336399478
- Cited by
- 263
- References
- 26
- FWCI
- 14.47
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.